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Introduction
Pathogenic mutations in some genes lead to a spectrum of vari-
ably penetrant phenotypes that span different organs and post-
mitotic tissue (1–4). For example, the same mutation in the auto-
phagic adaptor protein SQSTM1 (also known as p62) can cause 
Paget’s disease of the bone (PDB), rimmed vacuolar inclusion 
body myopathy (RV-IBM), amyotrophic lateral sclerosis (ALS), or 
frontotemporal dementia (FTD) (1). The term multisystem prote-
inopathy (MSP) has become useful to describe this growing family 
of genetic diseases that so far have been reported to have domi-
nant mutations in the pleotropic genes VCP, HNRNPA2B1, HNRN-
PA1,and SQSTM1 (1–4). Other disease-associated genes with vari-
ably penetrant phenotypic expression of RV-IBM, ALS, and FTD, 
yet no association with PDB, include TIA1 and MATR3 (5–7). One 
distinctive feature of the MSP pedigrees is that patients with the 
same mutation, and even the same mutation within a family, can 
manifest different phenotypes (i.e., PDB in 1 sibling and ALS in 
another sibling). MSP also unifies 2 key pathologic features in 
affected tissue: ubiquitinated aggregates and the accumulation 
of RNA-binding proteins with low-complexity sequence domains 
(LCDs) such as TDP-43 (4).
Mutations in several proteins that facilitate ubiquitin-depen-
dent autophagy such as VCP, SQSTM1, UBQLN2, and OPTN are 
associated with PDB, RV-IBM, ALS, and FTD (1, 2, 8, 9). Disease 
mutations in these proteins impair the degradation and clear-
ance of ubiquitinated inclusions, resulting in their accumulation. 
SQSTM1 is an autophagic adaptor protein with a UBA domain 
and an autophagosome-interacting motif (10). Most pathogenic 
variants in SQSTM1 are missense mutations within or truncations 
of the UBA domain (11). These mutations affect the oligomeriza-
Multisystem proteinopathy (MSP) involves disturbances of stress granule (SG) dynamics and autophagic protein degradation 
that underlie the pathogenesis of a spectrum of degenerative diseases that affect muscle, brain, and bone. Specifically, 
identical mutations in the autophagic adaptor SQSTM1 can cause varied penetrance of 4 distinct phenotypes: amyotrophic 
lateral sclerosis (ALS), frontotemporal dementia, Paget’s disease of the bone, and distal myopathy. It has been hypothesized 
that clinical pleiotropy relates to additional genetic determinants, but thus far, evidence has been lacking. Here, we provide 
evidence that a TIA1 (p.N357S) variant dictates a myodegenerative phenotype when inherited, along with a pathogenic 
SQSTM1 mutation. Experimentally, the TIA1-N357S variant significantly enhances liquid-liquid–phase separation in vitro and 
impairs SG dynamics in living cells. Depletion of SQSTM1 or the introduction of a mutant version of SQSTM1 similarly impairs 
SG dynamics. TIA1-N357S–persistent SGs have increased association with SQSTM1, accumulation of ubiquitin conjugates, 
and additional aggregated proteins. Synergistic expression of the TIA1-N357S variant and a SQSTM1-A390X mutation in 
myoblasts leads to impaired SG clearance and myotoxicity relative to control myoblasts. These findings demonstrate a 
pathogenic connection between SG homeostasis and ubiquitin-mediated autophagic degradation that drives the penetrance 
of an MSP phenotype.
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with ubiquitin-dependent autophagic degradation as a key media-
tor of the phenotypic outcome within the spectrum of RV-IBM, ALS, 
and FTD and shows the relevance of oligogenic mechanisms as one 
cause of neurodegenerative-neuromuscular disease.
Results
Digenic inheritance of an MSP-associated SQSTM1 mutation with a 
rare TIA1-N357S variant occurs in distal myopathy patients with RV 
pathology. We have previously described 2 unrelated families with 
distal myopathy and RV-IBM pathology caused by a c.1165+1 G>A 
splice donor variant in SQSTM1 (1). This variant generates a trun-
cated SQSTM1 protein that lacks its UBA domain and has been 
identified in patients with PDB and ALS (12, 13). Subsequent to this 
discovery, we identified an additional 3 patients with distal myop-
athy and a SQSTM1 p.P392L variant (15). Likewise, this SQSTM1 
p.P392L variant has been associated with dominantly inherit-
ed PDB, ALS, and FTD, phenotypes that were not present in our 
patients (12–14). Interestingly, these 3 patients had been previous-
ly identified in our cohort of distal myopathy patients carrying a 
rare TIA1 c.1070A>G; p.N357S; rs116621885 variant with a minor 
allele frequency (MAF) of 0.007. Surprisingly, our 3 previously 
reported SQSTM1 c.1165+1 G>A patients also carried the same rare 
TIA1 p.N357S variant. Dominant mutations in TIA1 are associated 
with WDM, a distal myopathy with RV-IBM pathology and, more 
recently, with ALS and FTD (6, 7). Notably, like with the WDM- and 
ALS-FTD–associated TIA1 mutations, the TIA1 p.N357S variant 
was present within the LCD at conserved residues (Figure 1A).
We used 2 approaches to identify additional myopathy patients 
with SQSTM1 mutations and the TIA1 p.N357S variant. First, 
we analyzed our neuromuscular disease gene panel sequencing 
results that included SQSTM1 and TIA1 for 1,294 patients with 
a presumed hereditary muscle disease (15). In addition, we per-
formed Sanger sequencing of SQSTM1 in 14 patients with unde-
termined distal myopathy and a WDM phenotype, whom we had 
previously identified as having the TIA1 p.N357S variant. These 
approaches identified a total of 8 patients from 6 families with the 
common SQSTM1 p.P392L mutation, 7 of whom also carried the 
TIA1 p.N357S variant. Notably, none of them had PDB, and all had 
distal myopathy with RV-IBM pathology, with the exception of 1 
patient, who carried only the SQSTM1 p.P392L mutation without 
the TIA1 p.N357S variant. This patient had a proximal phenotype, 
without RV-IBM muscle pathology, that had been characterized as 
limb-girdle muscular dystrophy.
We also identified 3 patients from 2 families with a previous-
ly reported SQSTM1 p.M404V mutation that was associated with 
PDB and dementia (29, 30). These patients also carried the TIA1 
p.N357S variant and had late-onset, distal predominant myopathy 
with RV-IBM pathology and no evidence of PDB. One additional 
patient with distal myopathy and RV-IBM pathology carried the 
TIA1 p.N357S variant and a rare synonymous SQSTM1 variant, 
c.1083C>T, p.S361S, which was previously identified in a patient 
with early-onset dementia (30). This synonymous mutation has a 
MAF of 0.00008 and is predicted to be disease causing.
MRI of patients’ lower extremities revealed extensive fat-
ty degenerative changes in distal muscles, evidenced by focal 
involvement of lower leg gastrocnemius and soleus muscles (Fig-
ure 1C). Muscle biopsies from a patient showed variation in fiber 
tion of SQSTM1 and its ability to recruit ubiquitinated aggregates 
to the autophagosome, suggesting that the pathogenesis of MSP 
and its related diseases are due in part to alterations in protein 
homeostasis and particularly to autophagic degradation of ubiq-
uitinated proteins in vulnerable tissues (11). One disease-associ-
ated SQSTM1 mutation that has been demonstrated to cause the 
full spectrum of MSP phenotypes (PDB, RV-IBM, ALS, and FTD) 
is a proline-to-leucine mutation at residue 392 (P392L) in the UBA 
domain (12–15). This single mutation is the most common genetic 
cause of PDB but is incompletely penetrant, suggesting that other 
genetic or environmental factors are needed for the phenotypic 
manifestation of PDB, RV-IBM, ALS, or FTD (16).
One distinctive pathologic feature seen in MSP-affected tis-
sues is the accumulation of cytoplasmic inclusions of RNA-bind-
ing proteins such as TDP-43 (4). Indeed, mutations in RNA-bind-
ing proteins with LCDs, including TARDBP, FUS, HNRNPA2B1, 
HNRNPA1, TIA1, and HNRPDL, cause dominantly inherited forms 
of MSP, ALS, FTD, and RV-IBM (3, 6, 7, 17–19). These RNA-bind-
ing proteins promote the assembly of membrane-less organelles 
such as stress granules (SGs) through the biophysical process of 
liquid-liquid phase separation (LLPS) that is mediated via the LCD 
(20). Importantly, disease-causing mutations in the LCD of these 
RNA-binding proteins alter their biophysical properties, increase 
their propensity to undergo LLPS, and result in the accumulation 
of poorly dynamic SGs that are believed to underlie cellular dys-
function and evolve into the pathological inclusions characteris-
tic of these diseases (7, 20, 21). Notably, TIA1 is a key component 
of cytosolic SGs (7). Dominantly inherited mutations within the 
LCD of TIA1 cause MSP or more discreet clinical manifestations 
of either ALS-FTD or a distinctive form of distal myopathy termed 
Welander distal myopathy (WDM) (6, 7). As with hnRNPA1, hnRN-
PA2B1, and TDP-43, disease mutations in the LCD of TIA1 alter its 
biophysical properties, promote LLPS, enhance fibrillization, and 
impair SG clearance as a mechanism of their pathogenicity (6, 7).
RV-IBMs are defined by a core set of pathologic features includ-
ing rimmed vacuoles (RVs) and inclusion bodies, seen in degen-
erative myopathies (22). RVs are present within some myofibers 
and contain autophagic and membranous debris, such as SQSTM1 
and MAP1LC3. Many proteins have been observed to accumulate 
as inclusions in RV-IBM tissue. These proteins include ubiquitin, 
β-amyloid, and TDP-43, with TDP-43 aggregation being specific for 
RV-IBMs (22). In many cases, protein inclusions and vacuolar debris 
are stained by Congo red and show birefringence, suggesting that 
the inclusions contain amyloidogenic proteins. A number of studies 
now establish that SQSTM1 and/or TDP-43 within myofibers serve 
as markers of muscle degeneration in RV-IBMs (23–26).
The relationship between SG homeostasis and autophagic pro-
tein degradation has been demonstrated in cell cultures (27, 28). 
Specifically, autophagy participates in SG clearance. Autophagy- 
mediated SG clearance may also require the ubiquitin segregase 
VCP (27, 28). Autosomally dominantly inherited mutations in VCP 
cause MSP, but whether the pathogenesis of MSP is mediated via its 
effect on SG homeostasis is not known (2). The present study iden-
tifies a rare variant in TIA1 that dictates the tissue specificity associ-
ated with SQSTM1 mutations. Digenic inheritance of a TIA1-N357S 
variant with a pathogenic SQSTM1 mutation causes a distal myopa-
thy with RV-IBM pathology. This finding connects SG homeostasis 
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p.P392L or a SQSTM1 p.M404V mutation and a TIA1 p.N357S 
variant, whereas family members carrying only a TIA1 p.N357S 
variant were unaffected (Figure 1B).
Importantly, sequencing of 50 patients (26 male, 24 female; 
average age, 73.7 ± 7.3 years) with previously reported pathogenic 
SQSTM1 mutations, including 40 patients with a SQSTM1-P392L 
mutation and 2 with a SQSTM1-M404V mutation manifesting with 
PDB but no muscle weakness, did not reveal any TIA1-N357S vari-
ant, supporting the idea that both variants are necessary for a mus-
cle phenotype with RV-IBM pathology (Supplemental Table 1) (31).
TIA1 N357S variant is overrepresented in distal myopathy patients. 
Although patients in these small pedigrees with only the TIA1 
p.N357S variant had no evidence of weakness, we reasoned that the 
rare TIA1 p.N357S variant may itself be enriched in patients with a 
distal myopathy phenotype. Indeed, in our large sequencing proj-
size and RVs consistent with RV-IBM (Figure 1D and Supplemen-
tal Figure 1B; supplemental material available online with this 
article; https://doi.org/10.1172/JCI97103DS1). In pathologically 
normal muscle, SQSTM1 is diffusely sarcoplasmic, and TDP-43 
and TIA1 are myonuclear (Supplemental Figure 1A). In contrast, 
SQSTM1 and TIA1 accumulated in the patient’s muscle sarco-
plasm and had some colocalization at RVs as determined by IHC 
(Figure 1E). In addition, TIA1 accumulated with other RNA-bind-
ing proteins such as TDP-43 and HNRNPA2B1 (Figure 1E and Sup-
plemental Figure 1C). Western blot (WB) analysis of skeletal mus-
cle from 1 patient showed normal steady-state levels for SQSTM1 
and TIA1 (Supplemental Figure 1D). Table 1 lists the clinical and 
laboratory characteristics for all SQSTM1-TIA1 patients included 
in this study. Digenic inheritance was found in 3 families, in which 
only examined affected family members carried both a SQSTM1 
Figure 1. Digenic inheritance of SQSTM1 and TIA1 variants leads to distal myopathy with RV-IBM pathology. (A) Linear diagram of the TIA1 protein high-
lighting conserved regions of the LCD. Distal myopathy–associated variant positions are shown in yellow and ALS and FTD variants in blue. (B) Pedigrees 
of families IV, VII, and IX showing segregation. DNA was only available for the patients indicated with an asterisk. (C) Muscle imaging findings for patient 
V-2 at age 54 years. Severe involvement of all calf muscles was seen on MRI T1-weighted images. The solid white arrow indicates normal muscle, and the 
arrowhead indicates atrophic muscle with fatty replacement. (D) H&E staining of a muscle biopsy of the right tibialis from patient XII-1 showing several 
fibers with RVs (arrows). Original magnification, 50 μm. (E) Immunofluorescence staining of TIA1 (red) with SQSTM1 (green in upper panel) or TDP-43 
(green in lower panel) revealed accumulation and partial colocalization of these proteins in the muscle biopsy from patient V-2. Both sets of images show 
a RV fiber. The dotted lines denote affected fiber. Scale bars: 50 μm.
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the allele frequency 0.1 for distal myopathy. A similar overrepresen-
tation of this TIA1 p.N357S variant was seen in 5 patients from a sec-
ond cohort of 51 patients with undiagnosed myopathy revealed by 
whole-exome sequencing. All 5 patients had a distal predominant 
phenotype with RV-IBM pathology, and 2 of these patients had an 
additional c.1165+1 G>A splice donor variant in SQSTM1 (1).
ect involving 1,293 patients with presumed hereditary myopathy, 
41 patients (3%) had the N357S variant (allele frequency 0.0162 
vs. 0.007 in the general population), and when this was stratified 
to those with a distal myopathy phenotype involving upper limbs as 
well, 17 of 86 (20%) of these patients carried the variant, including 1 
patient who was homozygous for the TIA1 p.N357S variant, making 
Table 1. Clinical characteristics of the patients
Family Sex Age Onset Family 
history
Pattern of weakness CK EMG Biopsy Muscle imaging Pagets/
dementia
SQSTM1 TIA1
I-1A Male 63 52 + Asymmetric; ankle 
dorsiflexion; wrist  
and finger extension; 
scapular winging
419 myopathic RVs, 
myofibrillar 
disarray




I-2A Male 47 42 + Asymmetric; ankle 
dorsiflexion; shoulder 
abduction; wrist extension




II-1A Male 60 50 – Asymmetric;  
ankle dorsiflexion;  
shoulder abduction; 
scapular winging
346 myopathic RVs; 
myofibrillar 
disarray




III-1B Male 65 35 – Ankle plantar and 
dorsiflexion; wrist  
and finger extension; 
scapular winging;  
proximal lower limbs
NA NA RVs TA, EDL/EHL, Gmed, 
Glat, S
–/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
IV-1 Female 68 NA + Ankle dorsiflexion;  
finger extension
NA NA NA NA –/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
IV-2 Male 62 41 + Ankle dorsiflexion; finger 
extension; scapular winging, 
abdominal and ankle 
plantar flexion
NA NA Myofibrillar 
disarray
S, mild Gmed –/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
V-2 Female 57 45 – (+?) Finger extension;  
thumb adduction/
abduction; facial weakness
2xUNL NA RVs Gmed, Glat, S, 
peronei
–/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S




RVs TA, Gmed, Glat –/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
VII-1 Male 50 48 – Ankle dorsiflexion; wrist  
and finger extension
2xUNL myopathic RVs TA, Gmed, Glat, S, 
glutei, paraspinal
–/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
VIII-1 Female 69 45 + Asymmetric ankle 
dorsiflexion; finger 
extension
ND ND ND ND –/– c.1175C>T; p.P392L c.1070A>G; 
p.N357S
IX-1 Male 76 45 + Ankle dorsiflexion; wrist  
and finger extension
500 myopathic NA NA ? c.1210A>G p.M404V c.1070A>G; 
p.N357S
IX-2 Female 62 50 + Ankle dorsiflexion; wrist  
and finger extension
NA NA Myofibrillar 
disarray
NA ? c.1210A>G p.M404V c.1070A>G; 
p.N357S
X-1 Male 68 55? ? Distal lower  
extremities
NA NA Myofibrillar 
disarray
TA, Gmed c.1210A>G p.M404V c.1070A>G; 
p.N357S
XI-1 Male 74 68 – Asymmetric finger extension; 
thumb abduction; mild finger 
flexion; ankle dorsiflexion; 
mild toe extension/flexion
1.5 × UNL myopathic RVs, 
myofibrillar 
disarray
Asymmetric TA, S, 
Gmed
–/– c.1083C>T, p.S361S c.1070A>G; 
p.N357S 
XII-1 Female 54 40 – Distal weakness in upper 
and lower extremities
NA myopathic NA All lower leg muscles 
except left Glat, deep 
toe flexors
–/– – c.1070A>G; 
p.N357S 
homozygous
EDL/EHL, long toe extensors; Gmed, gastrocnemius medialis; Glat, gastrocnemius lateralis; NA, not available; ND, not done; PNP, polyneuropathy;  
S, soleus; TA, tibialis anterior; UNL, upper normal limit. Previously reported patients from Aref. 1 and Bref. 15.
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to a lower protein concentration, indicating an increased propensity 
of mutant TIA1 to phase separate as a result of stronger intermolec-
ular protein-protein interactions (Figure 2A). Although the promo-
tion of LLPS with TIA1-EK was associated with an increased rate of 
amyloid-like fibril formation, as demonstrated by a time-dependent 
increase in thioflavin-T incorporation when compared with TIA1-
WT, we did not see this increase with purified TIA1-NS (Figure 2B).
The TIA1-N357S variant promotes LLPS and impairs SG clearance. 
To examine the impact of the TIA1-N357S (NS) mutation on LLPS, 
we constructed a phase diagram by measuring the coexistence line 
of a protein-depleted light phase and a protein-enriched dense 
phase as a function of temperature and protein concentration. Like 
the previously characterized TIA1-E384K (EK) mutant, the TIA1-NS 
mutation caused a significant leftward shift in the coexistence line 
Figure 2. TIA1-N357S variant promotes LLPS and disrupts SG dynamics. (A) Phase diagram of TIA1-WT, -EK, and -NS mapped at physiological con-
ditions. The mean concentration of the light phase (protein depleted phase) and SE are plotted. A quadratic equation was used to fit the trendlines 
(R2, WT, and NS = 0.99, EK = 0.98; P < 0.003 for NS vs. WT and P < 0.0002 for EK vs. WT, by χ2 test). Insets show characteristic DIC images of light, 
diffused phase, and dense phase droplets, respectively. (B) Thioflavin T fluorescence intensity of amyloid fibrils at 2.5 μM TIA1-WT, -EK, and -NS vari-
ants at the indicated time points. The spectrum of BSA (nonamyloid fibril–forming) was measured as a baseline. That baseline was subtracted from 
all the WT, EK and NS spectra at each time point. ***P < 0.001, by 2-way ANOVA with Tukey’s multiple comparisons test (NS, P > 0.1). (C) IF images 
of MEFs expressing GFP-TIA1-WT, -NS, or -EK immunostained with anti-G3BP1 (red) prior to 1 hour HS at 42°C, immediately after HS, or following 
a 30-minute HS recovery at 37°C. DAPI nuclear staining is shown in blue. Scale bars: 5 μm. (D) Bar graph of the percentage of cells containing TIA1/
G3BP1-positive SGs under the conditions described in C. Individual transfected cells were counted and are indicated as the total number of cells. 
Representative data were pooled from 3 independent experiments (n = 150~200). rec, recovery. (E) Graphical representation of the average relative 
fluorescence intensity (RFI) following photobleaching of individual SGs from MEFs expressing GFP-TIA1-WT, -NS, or -EK and treated for 1 hour with 
0.5 mM arsenite. Representative data were pooled from 3 independent experiments (n = 20~30). Error bars represent the mean ± SEM. (D and E)  
*P < 0.05, by 2-way ANOVA and 2-tailed Student’s t test.
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The effect of TIA1-NS and -EK variants on LLPS in vitro sug-
gested that these variants might affect the dynamics of SGs in 
vivo. To test this hypothesis, we expressed GFP-TIA1-WT, -NS, or 
-EK in mouse embryonic fibroblasts (MEFs) for 24 hours. Immu-
noblotting confirmed similar levels of expression for GFP-TIA1-
WT, -NS, and -EK (Supplemental Figure 2A). MEFs expressing 
GFP-TIA1 were fixed and stained with the SG marker G3BP1. 
Untreated GFP-TIA1-WT–expressing cells did not form SGs, 
while some SGs were detected in GFP-TIA1-NS– or -EK–express-
ing cells (Figure 2, C and D). Heat shock (HS) at 42°C induced SG 
formation in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 
1 hour. Upon return to 37°C for 30 minutes, approximately 10% 
of GFP-TIA1-WT–expressing MEFs contained SGs as compared 
with approximately 40% of MEFs expressing GFP-TIA1-NS or 
-EK (Figure 2, C and D). TIA1 in SGs is normally in rapid equi-
librium with TIA1 in the surrounding cytoplasm. We investigated 
whether TIA1-NS mutation affects its mobility within SGs. MEFs 
expressing GFP-TIA1-WT, -NS, or -EK were treated with 0.5 mM 
arsenite (AsIII) for 1 hour, and GFP-TIA1 SGs were subjected to 
fluorescence recovery after photobleaching (FRAP). Following 
photobleaching, approximately 65% of GFP-TIA1-WT fluores-
cence rapidly recovered, whereas GFP-TIA1-NS and -EK showed 
approximately 40% and 60% recovery, respectively (Figure 2E 
and Supplemental Figure 2B).
SQSTM1 participates in SG protein clearance. To explore the role 
of SQSTM1 in SG formation and clearance, we immunostained 
endogenous TIA1 and G3BP1 in control MEFs and MEFs lacking 
SQSTM1 (p62–/– MEFs). Untreated control or p62–/– MEFs did not 
form TIA1/G3BP1-positive SGs (Figure 3, A and B). Following 1 
hour of HS, approximately 95% of control MEFs and 70% of p62–/– 
MEFs contained SGs (Figure 3, A and B). Twenty minutes after 
reincubating the cells at 37°C, approximately 50% of the SGs dis-
appeared in the control MEFs and ultimately dissipated by 1 hour. 
In contrast, p62–/– MEFs had a slower SG clearance, with some cells 
maintaining SGs after 180 minutes (Figure 3, A and B). Persistent 
TIA1-positive SGs in p62–/– MEFs coimmunolocalized with an anti-
body that recognizes ubiquitin conjugates (Supplemental Figure 
3A). Consistent with SQSTM1 mediation of the clearance of SGs 
Figure 3. SQSTM1 is necessary for SG homeostasis. (A) Immunofluorescence images of control or SQSTM1-knockout MEFs (p62–/–) incubated at 42°C 
for 1 hour and returned to 37°C for the indicated durations followed by immunostaining for TIA1 (green) and G3BP1 (red) to detect SGs. (B) Graph of 
the percentage of cells containing TIA1/G3BP1-positive SGs as in A. Transfected cells were counted and are indicated as the total number of cells. 
Representative data were pooled from 3 independent experiments (n = 150~200). (C) Immunofluorescence images of MEFs expressing GFP-TIA1-WT, 
-NS, or -EK and immunostained with SQSTM1 antibody following incubation at 42°C for 1 hour and reincubation at 37°C for the indicated durations. 
(D) Bar graph of the percentage of GFP-TIA1/SQSTM1-positive SGs in C. Individual GFP-TIA1 SGs were counted and are indicated as the total number 
of SGs. Representative data were pooled from 3 independent experiments (n = 800~1000). Scale bars: 5 μm. Error bars represent the mean ± SEM.  
(B and D) *P < 0.05 by 2-way ANOVA and 2-tailed Student’s t test.
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via an autophagy-lysosomal pathway, we found that incubation 
of p62–/– MEFs with the lysosomal inhibitor bafilomycin A during 
HS recovery did not further augment the decrease in SG clearance 
seen with loss of SQSTM1 (Supplemental Figure 3B).
To determine whether there is a direct connection between 
TIA1 and SQSTM1, we immunostained for endogenous SQSTM1 
in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 1 hour of HS 
and following a 30-minute recovery to 37°C. We found that a sub-
set of GFP-TIA1-WT SGs colocalized with SQSTM1. Colocaliza-
tion of SQSTM1 and GFP-TIA1 was greater in GFP-TIA1-NS– and 
-EK–expressing MEFs than in GFP-TIA1-WT–expressing MEFs 
(Figure 3, C and D).
Defective ribosomal products (DRiPs) are prematurely ter-
minated and/or misfolded polypeptides (28, 32). They may form 
transient inclusions that colocalize with SQSTM1 and are target-
ed for clearance via the proteasome or autophagy (28, 32–34). 
DRiPs may also accumulate adjacent to and within SGs, which 
may lead to altered SG kinetics (28, 32). To determine wheth-
er SQSTM1 mediates the clearance of DRiP-containing SGs, we 
treated control and p62–/– MEFs with OP-puromycin to generate 
and label DRiPs. After 1 hour of HS, approximately 30% of SGs 
colocalized with DRiPs in control MEFs, and approximately 45% 
of SGs colocalized with DRiPs in p62–/– MEFs (Figure 4, A and B). 
Surprisingly, after 30 minutes of HS recovery, DRiP-containing 
SGs significantly decreased in control MEFs, but DRiP-containing 
SGs accumulated in p62–/– MEFs, suggesting that the clearance of 
aberrant SGs with DRiPs is SQSTM1 dependent (Figure 4, A and 
B). Likewise, we treated MEFs expressing GFP-TIA1-WT, -NS, or 
-EK with OP-puromycin to generate and label DRiPs as above. 
Following 1 hour of HS, approximately 35% of the GFP-TIA1-WT 
Figure 4. The presence of aggregated proteins increases TIA SG persistence in the presence of TIA1 mutations or loss of SQSTM1. (A) Immunofluo-
rescence images of control or p62–/– MEFs labeled with Alexa Fluor 594–azide (red) to detect DRiPs after incubation at 42°C for 1 hour and following a 
30-minute HS recovery. Representative data were pooled from 3 independent experiments (n = 350~450). Scale bars: 5 μm. (B) Graph of the percentage of 
TIA1 SGs labeled with Alexa Fluor 594–azide (red) detecting DRiPs in control or SQSTM1-knockout MEFs (p62–/–), incubated at 42°C for 1 hour and returned 
to 37°C for 30 minutes. Individual TIA1 SGs (green) were counted and are indicated as the total number of TIA1 SGs. Representative data were pooled from 
3 independent experiments (n = 350~450). (C) IF images of MEFs expressing GFP-TIA1-WT, -NS, or -EK and labeled with Alexa Fluor 594–azide (red) to 
detect DRiPs before HS, after incubation at 42°C for 1 hour, and following a 30-minute HS recovery period. Representative data were pooled from 3 inde-
pendent experiments (n = 350~450). (D) Bar graph of the percentage of TIA1 SGs labeled with DRiPs as in C. Individual TIA1 SGs (green) were counted and 
are indicated as the total number of TIA1 SGs. *P < 0.05 by 2-way ANOVA and 2-tailed Student’s t test.
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30-minute HS recovery, MEFs expressing mCherry-SQSTM1-PL, 
-MV, or -AX had persistent SGs in 80% of cells, suggesting that dis-
ease-associated SQSTM1 mutations delay SG clearance (Figure 6A).
To explore the synergy of a SQSTM1 disease mutation and the 
TIA1-N357S variant, we used patient-derived fibroblasts from 2 
control patients (fibroblast lines 112 and 409), 2 patients carrying 
the TIA1-N357S variant (fibroblast lines 107 and 319), and 1 patient 
carrying both SQSTM1 c.1165+1 G>A mutations, which generate a 
truncated SQSTM1-A390X mutation and a TIA1-N357S variant 
(fibroblast line 483). We treated low-passage fibroblasts with 0.5 
mM AsIII for 1 hour and then replaced AsIII-containing media 
for 40 minutes. Fibroblasts were immunostained for endogenous 
TIA1 and G3BP1. Untreated fibroblasts had no detectable SGs. 
Following 1 hour of AsIII treatment, all fibroblasts formed TIA1/
G3BP1-positive SGs (Figure 6, B and C). These SGs dissipated in 
all fibroblasts but were significantly increased in fibroblast line 
483, which contained both disease variants (Figure 6, B and C).
Coexpression of MSP-associated SQSTM1 mutations and TIA1-
N357S is myotoxic. To see whether the synergistic effect of SQSTM1 
mutations and TIA1 variants occurred in muscle cells, we cotrans-
fected C2C12 myoblasts with plasmids expressing mCherry-
SQSTM1-WT or mCherry-SQSTM1 carrying an MSP mutation 
(PL, MV, or AX) and GFP-TIA1-WT or GFP-TIA1 carrying a distal 
myopathy variant (EK or NS). After 60 minutes of HS, approximate-
ly 100% of myoblasts had TIA1-GFP–positive SGs, regardless of 
the mutation or variant (Figure 6D). In contrast, after 60 minutes 
of HS recovery, myoblasts expressing a disease-associated SQSTM1 
mutation with a TIA1 variant had an increase in persistent SGs as 
compared with that seen in mCherry-SQSTM1-WT–expressing 
myoblasts (Figure 6D). To determine  whether coexpression of 
SGs colocalized with DRiPs, and this number decreased upon HS 
recovery (Figure 4, C and D). In contrast, GFP-TIA1-NS and -EK 
SGs colocalized more robustly with DRiPs following HS, and this 
association persisted upon HS recovery (Figure 4, C and D).
We reasoned that since DRiPs were misfolded proteins, then 
TIA1 may similarly accumulate with other misfolded and aggre-
gated proteins at SGs. To test this, we expressed an aggrega-
tion-prone 25-kDa C-terminal TDP-43 fragment with an mCherry 
tag (mCherry-TDP-CTF) in control and p62–/– MEFs and subjected 
them to 1 hour of HS followed by 30 minutes of recovery. Immu-
nofluorescence (IF) for endogenous TIA1 revealed that, upon HS, 
TIA1 and mCherry-TDP-CTF colocalized in both cell types (Figure 
5, A and B). However, upon recovery in the p62–/– MEFs, approx-
imately 80% of the persistent TIA1-positive SGs also contained 
mCherry-TDP-CTF as compared with approximately 20% of the 
SGs in control MEFs (Figure 5, A and B).
MSP-associated SQSTM1 mutations impair TIA1-positive SG 
homeostasis. To determine whether SQSTM1 disease mutations 
identified in MSP patients affected the clearance of TIA1-contain-
ing SGs, MEFs expressing mCherry, mCherry-SQSTM1-WT, or 
mCherry-SQSTM1 carrying the MSP mutation SQSTM1-P392L 
(PL), SQSTM1-M404V (MV), or SQSTM1-A390X (AX) were immu-
nostained with antibodies against endogenous TIA1. Without HS, 
MEFs expressing mCherry or mCherry-SQSTM1-WT did not form 
SGs (Figure 6A). In contrast, even without HS, MEFs expressing 
the mCherry-SQSTM1 disease mutations (PL, MV, or AX) had 
TIA1-positive SGs (Figure 6A). As expected, most cells contained 
SGs following 1 hour of HS, and after 30 minutes of post-HS recov-
ery, approximately 50% of SGs were cleared from MEFs express-
ing mCherry or mCherry-SQSTM1-WT. In contrast, following a 
Figure 5. TDP-43 aggregates increase TIA SG persistence in the loss of SQSTM1. (A) Immunofluorescence images of endogenous TIA1 (green) from control 
or p62–/– MEFs transfected with an mCherry-tagged TDP-43 C-terminal fragment (red) after incubation at 42°C for 1 hour and following a 30-minute HS 
recovery. Representative data were pooled from 3 independent experiments (n = 350~450). (B) Bar graph showing the percentage of TIA1 SGs with mCherry 
TDP-43 C-terminal fragment in control or p62–/– MEFs from A. Individual TIA1 SGs (green) were counted and are indicated as the total number of TIA1 SGs. 
DAPI nuclear staining is shown in blue. Scale bars: 5 μm. Error bars represent the mean ±  SEM. *P < 0.05, by 2-way ANOVA and 2-tailed Student’s t test.
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Figure 6. SQSTM1 disease mutations alter SG kinetics and synergistically mediate myotoxicity with TIA1-N357S. (A) Bar graph showing the 
percentage of MEFs containing endogenous TIA1-positive SGs. MEFs were transfected with mCherry, mCherry-SQSTM1-WT, or 1 of 3 different dis-
ease mutations (PL, MV, or AX) incubated at 42°C for 1 hour and subsequently returned to 37°C for the indicated durations. Transfected cells were 
counted and are indicated as the total number of cells. Representative data were pooled from 3 independent experiments (n = 450~550). (B) Bar 
graph showing the percentage of fibroblasts containing TIA1/G3BP1-positive SGs from fibroblasts of control patients (fibroblast lines 112 and 409), 
patients carrying the TIA1-N357S variant (fibroblast lines 107 and 319), and a patient carrying both a SQSTM1-A390X mutation and a TIA1-N357S 
variant (fibroblast line 483) immediately following 0.5 mM AsIII treatment for 1 hour or following a 40-minute recovery. (C) Immunofluorescence 
images of patients’ fibroblasts detailed in B, immunostained with TIA1 (green) and G3BP1 antibodies (red) before, immediately following 0.5 mM 
AsIII treatment for 1 hour, and following a 40-minute recovery. DAPI nuclear staining is shown in blue. Scale bars: 5 μm. Representative data were 
pooled from 3 independent experiments (n = 120~150). (D) Bar graph showing the percentage of C2C12 myoblasts containing TIA1-positive SGs. C2C12 
myoblasts were cotransfected with mCherry, mCherry-SQSTM1-WT, or mCherry-SQSTM1 with 1 of 3 different disease mutations (PL, MV, or AX) and 
GFP-TIA1-WT or 1 of 2 variants (EK or NS) incubated at 42°C for 1 hour and subsequently returned to 37°C for the indicated durations. (E) Bar graph of 
LDH release from C2C12 myoblasts similar to those in D, before HS and after 1 hour of HS, with an additional 1-hour recovery at 37°C. The absorbance 
of the samples was measured at 492 nm. The reference wavelength at 680 nm was measured. Representative data were pooled from 3 independent 
experiments (n = 150~200). Error bars represent the mean ± SEM. *P < 0.05, by 2-way ANOVA and 2-tailed Student’s t test.
Downloaded from http://www.jci.org on March 13, 2018.   https://doi.org/10.1172/JCI97103
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 1 7 3jci.org   Volume 128   Number 3   March 2018
The findings in our study may relate to other forms of MSP. 
Specifically, mutations in VCP, a ubiquitin segregase necessary for 
autophagic protein degradation, were the first identified cause of 
MSP (originally termed IBMPFD, for inclusion body myopathy- 
associated with Paget’s disease of the bone and fronto-temporal 
dementia) (2). Recent studies confirm the original report that 90% 
of patients develop RV-IBM, 42% develop PDB, and 30% develop 
FTD, but also expand the degenerative phenotypes to include 9% 
of patients with ALS and 4% with parkinsonism (37). Why some 
patients with VCP mutations develop RV-IBM and others PDB is 
not clear, but as with our study, it probably relates to oligogenic 
inheritance. For example, patients manifesting with VCP-associat-
ed dementia are more likely to carry an APOE4 allele (38). Some 
VCP mutations, like the SQSTM1-P392L mutation have low MAFs 
in the general population. Rare variants in VCP and SQSTM1 are 
identified as overrepresented in large cohorts of patients with spo-
radic PDB, IBM, ALS, or dementia, suggesting that they may be risk 
factors for disease or have reduced penetrance (13, 14, 30, 39–43).
Digenic inheritance can manifest in several ways. For example, 
the inheritance of a second genetic variant can affect the primary 
gene’s mutant phenotype by modifying its severity or age of onset. 
Another example occurs when a single genetic mutation may have a 
reduced penetrance, and the inheritance of a mutation in a second 
gene unmasks the variable expressivity of the primary mutation. 
Examples of true digenic inheritance, in which the inheritance of 
2 variants on 2 different genes is necessary to manifest disease, are 
rare and challenging to prove. One recent example is found in some 
forms of facioscapulohumeral muscular dystrophy type 2 (FSHD2), 
in which a patient must inherit both a permissive D4Z4 allele and 
an SMCHD1 variant on different chromosomes (44). The strength 
of this example relates to its presence in multiple families and the 
convincing mechanistic interaction between the 2 alleles.
While autophagy has been implicated in SG clearance, this is 
the first report to our knowledge to demonstrate a role for SQSTM1 
in SG dynamics. RNA-binding proteins such as TIA1 initiate gran-
ule formation via their LCDs by promoting reversible LLPS (45). 
Persistent SGs may occur when LLPS converts the LCD into an irre-
versible amyloid-like structure (20). Our data suggest that, while 
the TIA-EK and -NS variants promote phase separation, only the 
TIA1-EK variant enhances its amyloidogenic conversion. This may 
explain why heterozygous TIA1-E384K mutations lead to WDM, 
yet TIA1-N357S variants require a SQSTM1-mutant environment 
for penetrance. Loss of SQSTM1 or SQSTM1-mutant expression 
leads to the accumulation of undegraded, ubiquitinated, and insol-
uble proteins (46). The presence of misfolded and aggregate-prone 
proteins increases SG formation and persistence in cell culture (32, 
47). Likewise, we found that in the setting of SQSTM1-knockout or 
-mutant expression, TIA1-persistent SGs colocalized with aggre-
gated proteins such as DRiPs and a C-terminal TDP-43 fragment. 
While it is possible that SQSTM1 directly shuttles ubiquitinated and 
aggregated TIA1 to the autophagosome, we propose an alternate 
model. Specifically, the presence of the SQSTM1 mutations leads to 
the cytosolic accumulation of aggregated proteins that then serve 
as a nidus for RNA granule conversion to an irreversible state.
The mechanism whereby disturbances in RNA granule dynam-
ics and persistence of poorly dynamic SGs impair cell function 
in general or cause muscle degeneration in particular remains 
SQSTM1-AX and TIA1-NS synergistically enhanced myotoxici-
ty, we performed a lactate dehydrogenase (LDH) release assay on 
C2C12 myoblasts cotransfected with plasmids expressing mCherry-
SQSTM1-WT or mCherry-SQSTM1-AX and GFP-TIA1-WT or GFP-
TIA1-NS before HS and after  60 minutes of HS with an additional 
60 minutes of HS recovery, a time point at which persistent SGs 
are present. Consistent with a synergistic effect, SQSTM1-AX– and 
TIA1-NS–expressing myoblasts had increased LDH release as com-
pared with the SQSTM1-WT or TIA1-WT transfectants (Figure 6E).
Discussion
The present study identified 14 patients from 9 families with dis-
tal myopathy and RV-IBM pathology, who all carried a previously 
reported pleotropic mutation in SQSTM1 and a rare TIA1-N357S 
variant. These patients did not manifest other phenotypes asso-
ciated with SQSTM1 mutations such as PDB, ALS, or FTD at the 
time of examination. Importantly, SQSTM1 and TIA1 accumulat-
ed with TDP-43 in patients’ muscle tissue, suggesting that they 
participate in the disease pathogenesis. While the connection 
between SG clearance and autophagic protein degradation has 
been previously suggested, the present study provides human 
genetic evidence for a pathologic interaction (27, 28). These data 
support the notion that inheritance of a TIA1 variant can shift the 
phenotypic spectrum of SQSTM1 mutations to myodegeneration.
Mutations in SQSTM1 were initially identified in patients 
with familial PDB and included the SQSTM1-P392L and c.1165+1 
G>A splice acceptor mutations (12). Notably, the SQSTM1-P392L 
mutation was found in approximately 9% of patients with spo-
radic PDB, making it the most common genetic cause of the dis-
ease (12). Later reports identified other missense mutations in or 
truncations of the UBA domain of SQSTM1, including the M404V 
mutation as causative in familial and sporadic PDB (29). Subse-
quently, SQSTM1 mutations including the P392L and c.1165+1 
G>A were identified in patients with familial ALS and/or FTD (13, 
14, 35). In 2015, we described 3 patients who had distal myopathy 
and RV-IBM pathology with the SQSTM1 c.1165+1 G>A mutation 
(1). Since the same SQSTM1 mutation can generate distinct pheno-
types in different patients, we suggested that SQSTM1-associated 
disease be termed multisystem proteinopathy type 4 (MSP4) (1). 
MSP defines a pleotropic genetic disease, in which a single gene 
and mutation can manifest as distinct disease phenotypes that 
include PDB, RV-IBM, ALS, and FTD.
We previously reported a TIA1-E384K founder mutation as 
the cause of WDM, an autosomal dominant distal myopathy with 
RV-IBM pathology (6). The phenotype of patients with WDM is sim-
ilar to that of the SQSTM1-TIA1 patients described in this report. 
WDM is a progressive, late-onset myopathy that typically manifests 
in the fifth decade. A very small number of WDM patients who are 
homozygous for the TIA1-E384K variant have an earlier onset and 
more rapid disease progression, suggesting that the TIA1-E384K 
mutation exerts a dose-dependent, dominant effect (36). Similar-
ly, we identified 1 patient in our cohort with distal myopathy who 
was homozygous for the TIA1-N357S variant. This patient did not 
have a second mutation in SQSTM1. The TIA1-N357S variant was 
overrepresented in our myopathy cohort and was present in 20% of 
our distal myopathy patients. These data support the idea that the 
TIA1-N357S variant may itself be a risk factor for distal myopathy.
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enrichment and sequencing were performed at the Institute for Molec-
ular Medicine of Finland (FIMM), Biomedicum in Helsinki, Finland, 
and at the Wellcome Trust Centre for Human Genetics (WTCHG) 
in Oxford, United Kingdom, using the Illumina HiSeq1500 and HiS-
eq2000 platforms. The sequencing raw data were mapped against the 
human reference genome GRCh37/hg19. Data analysis was performed 
using an in-house pipeline as described earlier (15).
Indexed genomic DNA (gDNA) libraries were prepared from gDNA 
using a TruSeq DNA Preparation Kit (Illumina), and exome capture 
was done using a TruSeq Exome Enrichment Kit (Illumina) according 
to the manufacturer’s protocol. Sequencing was performed with 100-
bp paired-end reads on a HiSeq2000 (Illumina). Reads were aligned 
to the human reference genome with NovoAlign or Burrows-Wheeler 
Aligner. Variants were called with SAMtools (http://samtools.source-
forge.net/) and annotated with SeattleSeq (http://snp.gs.washington.
edu/SeattleSeqAnnotation138/). Coverage across genomic intervals 
was calculated using bedtools (http://bedtools.readthedocs.io/en/ 
latest/). Genomic coordinates for regions targeted by the whole- exome 
capture kit were provided by Illumina. High-throughput sequencing 
results were verified by Sanger sequencing. Allele frequencies for the 
general population were taken from gnomAD (51).
Protein purification, in vitro fibrillization, and phase diagram. 
Recombinant DNA for TIA1-WT, N387S, and E384K constructs were 
cloned into the pETite N-His SUMO Kan vector (Lucigen). Plasmids 
were chemically transformed into BL21_DE3 cells (Lucigen). Pro-
tein purification, in vitro fibrillization, and phase diagram protocols 
described in Mackenzie et al. (7) were followed. For the phase dia-
gram, the spectrum of BSA (nonamyloid fibril–forming) was measured 
as a baseline. That baseline was subtracted from all the WT, E384K, 
and N357S spectra at each time point, respectively.
Muscle pathology, reagents, and antibodies. Frozen muscle sections 
were processed for routine histochemical analysis, including H&E, 
modified Gomori trichrome, combined succinate dehydrogenase–
cytochrome oxidase, ATPase at pH 9.2, pH 4.3 and reduced nicotin-
amide adenine dinucleotide–tetrazolium reductase.
The following antibodies were used: anti-TIA1 polyclonal anti-
body (C-20; Santa Cruz Biotechnology; catalog sc-1751; 1:500 for 
WB, 1:100 for IF); anti-G3BP1 polyclonal antibody (Proteintech; cat-
alog 13057-2-AP; 1:100 for IF); anti-p62 polyclonal antibody (Protein-
tech; catalog 18420-1-AP; 1:1,000 for WB and 1:100 for IF); anti-GFP 
polyclonal antibody (MilliporeSigma; catalog G1544; 1:500 for WB); 
anti-Ub monoclonal antibody (FK2, Biomol; catalog PW-8810; 1:500 
for WB and 1:100 for IF); anti–Ub polyclonal antibody (Dako; catalog 
Z0458; 1:5,000 for WB and 1:100 for IF); and anti-GAPDH polyclonal 
antibody (Cell Signaling Technology; catalog 2118; 1:1,000 for WB). 
For the detection of endogenous proteins in patients’ muscle biopsies, 
the following antibodies were used for IF: anti–TIA1 polyclonal anti-
body (Abcam; catalog ab61700; 1:100) and anti–p62 polyclonal anti-
body (MilliporeSigma; catalog P0067; 1:100).
Cell culture and transient transfection. Fibroblasts were cultured 
in Fibroblast Basal Medium FGM-2 (Lonza; catalog CC-313) supple-
mented with FGM-2 SingleQuot Kit & Growth Factors (Lonza; catalog 
CC-4126), as recommended by the manufacturer, at 37°C and 5% CO2 
in a humidified incubator. Immortalized control and p62–/– MEFs were 
provided by M. Komatsu (Niigata University, Niigata, Japan). MEFs 
were maintained in DMEM (Gibco, Thermo Fisher Scientific; cata-
log 11965-084); 10% FBS (Atlanta Biologicals; S10350H); 50 μg/ml 
unclear. One possibility is that disturbance of the SG dynamics 
results in the impairment of functions normally conducted with-
in these complex, membrane-less organelles (e.g., remodeling of 
messenger ribonucleoprotein particles [mRNPs] or participating in 
intracellular signaling cascades). Alternatively, the condensed liq-
uid environment of the SG may promote untoward fibrillization of 
RNA-binding proteins to produce insoluble, pathological species. 
Indeed, in vitro LLPS promotes a rapid fibrillization of RNA-bind-
ing proteins that occurs within the condensed liquid phase, result-
ing in the accumulation of potentially toxic species (20).
An enigmatic feature of the syndrome MSP and most of the 
constituent diseases (ALS, FTD, and RV-IBM) is the prominence 
of TDP-43 pathology, despite tremendous heterogeneity in its 
genetic etiology. Thus, mutations in genes as diverse as VCP, 
SQSTM1, C9ORF72, HNRNPA1, HNRNPA2B1, TARDBP, and TIA1 
culminate in highly similar histopathology, in which cytoplasmic 
deposition of fibrillar TDP-43 is a prominent feature. Notably, 
even when disease mutations occur in other RNA-binding proteins 
prone to fibrillization, such as TIA1, the histopathological picture 
is dominated by TDP-43 pathology (7). A likely explanation for 
this phenomenon is that there are differences in the stability of 
fibrils assembled from various RNA-binding proteins. Indeed, 
it was recently demonstrated that recruitment of TDP-43 to SGs 
results in an abrupt reduction in the mobility of this protein and 
conversion to an SDS-resistant, poorly soluble species, whereas 
other RNA-binding proteins recruited to the same SGs remain 
mobile and soluble (7).
Cytosolic TDP-43 accumulation has been shown to elicit 
cellular toxicity via several mechanisms including disruptions in 
RNA transport, splicing, and nucleocytoplasmic shuttling (48). 
Interestingly, autophagic inhibition leads to the cytosolic accu-
mulation in TDP-43 (49). This effect also occurs in differentiated 
skeletal muscle, further connecting autophagic impairment with 
SG pathology(49). Interestingly, enhancing autophagy has been 
shown to be protective in the setting of TDP-43 accumulation (50).
MSP may represent an alternative manifestation of digen-
ic inheritance. Specifically, a mutation on gene X (i.e., SQSTM1 
or VCP) can lead to variable expressivity of multiple phenotypes 
(PDB, ALS, FTD, or RV-IBM). Inheritance of a variant on gene Y 
(TIA1), while impenetrant alone, dictates the phenotypic expres-
sion of gene X (distal myopathy with RV-IBM pathology). This 
model explains the genetics of MSP but may also relate to the phe-
notypic penetrance seen within the ALS-FTD spectrum. In addi-
tion, our model supports a pathomechanistic connection between 
SG homeostasis and ubiquitin-mediated autophagic degradation.
Methods
Genetic studies. A cohort of 1,293 patients with presumed hereditary 
myopathy were sequenced using a targeted high-throughput sequenc-
ing panel called MYOcap. The panel covered the exons, as well as some 
3′- and 5′-UTRs of selected genes either reported to cause muscle dis-
ease or to be functionally related to such genes (15). The MYOcap panel 
has been regularly updated, and samples of the cohort were sequenced 
with 4 versions covering 180, 236, 265, and 297 genes, respectively. 
The TIA1 and SQSTM1 genes were included in all versions. Specific 
probes were manufactured by Roche NimbleGen (SeqCap EZ Choice 
Library). DNA was extracted from blood by standard methods, and 
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and OP-puromycin–containing media were replaced for the indicated 
time (Figure 4 legend). Fixation and Click-iT reactions were performed 
with Alexa Azide 594 according to the manufacturer’s instructions 
(Life Technologies, Thermo Fisher Scientific; catalog C10399). MG132 
(C2211) and BAFA (B1793) were purchased from MilliporeSigma. Con-
trol MEFs and p62–/–  were treated with MG132 (20 μM) or BAFA (200 
nM) for 1 hour at 37°C with 5% CO2 after 1 hour of HS at 42°C .
Fluorescence recovery after photobleaching. Control MEFs were 
grown on 1.5 glass-bottomed 35-mm dishes (MatTek; P35G-1.5-10-C) 
and transfected with GFP-human TIA1 for 24 hours prior to imaging. 
Immediately before imaging, the medium was replaced with phenol 
red-free medium (Gibco, Thermo Fisher Scientific; catalog 21063029) 
containing 10% FBS, 50 μg/ml penicillin-streptomycin, 1% sodium 
pyruvate, and 1% nonessential amino acid. The live-cell samples were 
treated with 0.5 mM AsIII for 1 hour and placed on a heated chamber 
at 37°C with 5% CO2. Imaging and photobleaching were performed 
with a ×40 oil objective using a Nikon A1Rsi confocal microscope. 
Before bleaching, the images of prebleached TIA1 aggregates were 
taken. A 488-nm laser was used to photobleach TIA1 aggregates for 
500 ms. Immediately after bleaching, the images were collected every 
second for a total of 150 seconds as a post-bleached sample. The flu-
orescence intensities of post-bleached TIA1 aggregates (Ft) were indi-
vidually measured. In the meantime, the fluorescence intensities of 
nonbleached TIA1 aggregates were measured as a reference control 
(Fref). Also, the fluorescence intensities of nonbleached and non-
transfected background were measured as a background control (Fb). 
The photobleaching rate (r) was calculated by comparing the fluores-
cence of the reference before (Fref0) and after (Fref) photobleaching: 
r = Fref/Fref0. The average of TIA1 aggregates fluorescence intensi-
ties (F) in different cells (n ≥ 5 cells containing TIA1 aggregates) was 
calculated as follows: F = (Ft – Fb)/r.
LDH assay. C2C12 cells were transfected with Cherry-p62-WT or 
AX along with GFP-TIA1-WT, -NS, or -EK 24 hours before the LDH 
assay. Cells were split into 96-well plates with 2 × 105 cells per well, 
in triplicate. Cells were then incubated for 1 hour at 42°C in 5% CO2 
and returned to 37°C in 5% CO2 for a 1-hour recovery. The LDH assay 
was performed according to the manufacturer’s instructions (Roche; 
catalog 04 744 926 001).
Statistics. A 2-tailed Student’s t test between 2 groups and 2-way 
ANOVA between more than 2 groups were performed. For all tests, 
P values of less than 0.05 were considered statistically significant. 
Data are presented as the mean ± SEM.
Study approval. All evaluations and genetic studies were conduct-
ed with the approval of the Human Studies Committee of Washington 
University and the IRB of Helsinki University. Written informed con-
sent was provided by all study participants, in accordance with Decla-
ration of Helsinki principles.
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